Literature DB >> 12749967

Changes in sensory processing in the spinal dorsal horn accompany vincristine-induced hyperalgesia and allodynia.

H-R Weng1, J V Cordella, P M Dougherty.   

Abstract

Abnormal sensation and pain are major dose-limiting factors in cancer chemotherapy with vincristine. In this study, we have adapted a model of this condition by using repeated daily intraperitoneal injections of vincristine in rats. Mechanical allodynia and hyperalgesia without change in responses to thermal stimuli were first observed following 5-8 days of vincristine treatment (0.1mg/kg/day) and then persisted throughout the remainder of the treatment interval (2-3 weeks). Electrophysiological recording from wide dynamic range (WDR) neurons in the lumbar (L4-L5) spinal dorsal horn in hyperalgesic rats demonstrated significantly increased spontaneous activity and after-discharges to noxious mechanical stimuli (von Frey filaments with a bending force greater than 58.02mN, skin compression 1.3 and 3N, 1mm(2)), increased acute A- and C-fiber responses, after-discharges and abnormal 'wind-up' to electrical stimuli (5mA, 2ms) at 0.1Hz applied across the receptive field. These results suggest a state of central sensitization develops in spinal WDR neurons with repeated vincristine treatment that contributes to the spontaneous pain and hyperalgesia seen in patients and the hyperresponsiveness to sensory stimuli seen in animals treated with vincristine.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12749967     DOI: 10.1016/s0304-3959(02)00445-1

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  54 in total

1.  Cellular and functional evidence for a protective action of neurosteroids against vincristine chemotherapy-induced painful neuropathy.

Authors:  Laurence Meyer; Christine Patte-Mensah; Omar Taleb; Ayikoe Guy Mensah-Nyagan
Journal:  Cell Mol Life Sci       Date:  2010-04-30       Impact factor: 9.261

2.  Novel small molecule α9α10 nicotinic receptor antagonist prevents and reverses chemotherapy-evoked neuropathic pain in rats.

Authors:  Elzbieta P Wala; Peter A Crooks; J Michael McIntosh; Joseph R Holtman
Journal:  Anesth Analg       Date:  2012-05-18       Impact factor: 5.108

3.  Wireless transcutaneous electrical nerve stimulation device for chemotherapy-induced peripheral neuropathy: an open-label feasibility study.

Authors:  Jennifer S Gewandter; Jenna Chaudari; Chinazom Ibegbu; Rachel Kitt; Jennifer Serventi; Joy Burke; Eva Culakova; Noah Kolb; Kathleen A Sluka; Mohamedtaki A Tejani; Nimish A Mohile
Journal:  Support Care Cancer       Date:  2018-08-27       Impact factor: 3.603

4.  MAPK signaling downstream to TLR4 contributes to paclitaxel-induced peripheral neuropathy.

Authors:  Yan Li; Hongmei Zhang; Alyssa K Kosturakis; Ryan M Cassidy; Haijun Zhang; Ross M Kennamer-Chapman; Abdul Basit Jawad; Cecilia M Colomand; Daniel S Harrison; Patrick M Dougherty
Journal:  Brain Behav Immun       Date:  2015-06-09       Impact factor: 7.217

5.  Minocycline prevents impaired glial glutamate uptake in the spinal sensory synapses of neuropathic rats.

Authors:  H Nie; H Zhang; H R Weng
Journal:  Neuroscience       Date:  2010-08-03       Impact factor: 3.590

6.  Chronic pain and impaired glial glutamate transporter function in lupus-prone mice are ameliorated by blocking macrophage colony-stimulating factor-1 receptors.

Authors:  Xisheng Yan; Dylan W Maixner; Fen Li; Han-Rong Weng
Journal:  J Neurochem       Date:  2017-02-01       Impact factor: 5.372

7.  Blocking the GABA transporter GAT-1 ameliorates spinal GABAergic disinhibition and neuropathic pain induced by paclitaxel.

Authors:  Ruchi Yadav; Xisheng Yan; Dylan W Maixner; Mei Gao; Han-Rong Weng
Journal:  J Neurochem       Date:  2015-04-23       Impact factor: 5.372

8.  Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats.

Authors:  E J Rahn; A Makriyannis; A G Hohmann
Journal:  Br J Pharmacol       Date:  2007-06-18       Impact factor: 8.739

Review 9.  Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain.

Authors:  J Guindon; A G Hohmann
Journal:  Br J Pharmacol       Date:  2007-11-12       Impact factor: 8.739

10.  Anti-allodynic effect of theoesberiven F in a vincristine-induced neuropathy model.

Authors:  Seunguk Bang; Yee Suk Kim; Sang Rok Jeong
Journal:  Exp Ther Med       Date:  2016-05-26       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.